Pharma DTC Patient Engagement Platform Development

A pharma DTC engagement platform delivers branded and unbranded patient communication: disease education, product information under FDA advertising rules, copay and savings programs, adherence support, and injection or device training. Two requirements distinguish it from consumer health software. Promotional content must present fair balance including important safety information, and every channel must capture and route potential adverse events. Our work sits within our broader pharma and life sciences practice.

Our pharma DTC engagement services cover content delivery, program enrollment, savings administration, adherence tooling, and safety capture integration. Adverse event routing is scoped as core infrastructure rather than a feature, because a patient-facing platform without a functioning capture path creates regulatory exposure from the day it launches. Engagements typically open with a review of intended channels, program design, and how safety reporting currently operates. Deliverables are structured so brand, medical, safety, and legal stakeholders can review independently.

The benefits concentrate in controlled patient communication, reliable safety capture, and program administration efficiency. Manual copay program administration is expensive and error prone, and eligibility errors carry Anti-Kickback exposure rather than merely financial cost. Structured safety capture also converts a recurring compliance gap into a system property. We publish no figures on adherence, persistence, or program performance, because those depend entirely on product, disease area, and patient population.

We deliver pharma DTC engagement projects in gated phases so brand, medical, safety, and legal stakeholders approve direction before engineering cost accumulates. Discovery establishes channels, program design, and safety routing requirements. We sequence adverse event capture before launch of any patient-facing channel, without exception, because a live channel without a working capture path is a regulatory problem on day one. Content controls are reviewed with medical and regulatory before any patient sees material.

Patient-facing pharma software operates under FDA advertising regulation requiring fair balance and important safety information, Anti-Kickback constraints on patient inducements, and pharmacovigilance obligations triggered by patient-reported events. Privacy is frequently misunderstood here: manufacturers are generally not HIPAA covered entities, so patient data collected directly typically falls under FTC authority, the Health Breach Notification Rule, state laws including Washington My Health My Data, and CCPA rather than HIPAA. Taction holds ISO 27001 certification and builds to the framework that actually applies.

Taction Software was founded in 2013 and has spent over 12 years building healthcare and life sciences software, delivering more than 200 healthcare projects from four US offices in Chicago, Cheyenne, Austin, and Sacramento, with ISO 27001 certification. Our relevant discipline here is refusing to launch a patient channel before adverse event routing works. That sequencing occasionally delays launch and consistently prevents the regulatory problem that follows a live channel with no capture path. Our leadership brings more than 20 years of personal experience in the field.

Pharma DTC engagement pricing depends on scope, channel count, program complexity, and safety integration requirements. A branded content site costs considerably less than a platform adding savings program administration, adherence tooling, and multi-channel safety capture. Safety integration is scoped explicitly because it is a launch prerequisite rather than an optional module. Discovery produces an itemized, fixed-scope estimate with phase-level breakdown. Cloud infrastructure, hub service fees, and media costs are separate from engineering.